As a third-generation ALK-TKI, lorlatinib has a distinct safety profile that is different from those of other ALK-TKIs, including hyperlipidemia, peripheral neuropathy, and central nervous system AEs. The gene discussed is ALK; the disease is peripheral neuropathy.